Disease-modifying therapeutic directions for Lewy-Body dementias.
Disease-modifying therapeutic directions for Lewy-Body dementias.
复制标题
DOI：
10.3389/fnins.2015.00293
复制
发表时间：
2015
影响因子：
4.3
通讯作者：
Narayanan NS
中科院分区：
文献类型：
--
作者：
Zhang Q;Kim YC;Narayanan NS
Dementia with Lewy bodies (DLB) is the second leading cause of dementia following Alzheimer's disease (AD) and accounts for up to 25% of all dementia. DLB is distinct from AD in that it involves extensive neuropsychiatric symptoms as well as motor symptoms, leads to enormous societal costs in terms of direct medical care and is associated with high financial and caregiver costs. Although, there are no disease-modifying therapies for DLB, we review several new therapeutic directions in treating DLB. We discuss progress in strategies to decrease the level of alpha-synuclein, to prevent the cell to cell transmission of misfolded alpha-synuclein, and the potential of brain stimulation in DLB.
